Jason Garland Sells 733 Shares of Repligen (NASDAQ:RGEN) Stock

Repligen Corporation (NASDAQ:RGEN) CFO Jason Garland sold 733 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Repligen Price Performance

Shares of Repligen stock traded up $1.78 on Friday, reaching $147.01. 1,965,039 shares of the stock were exchanged, compared to its average volume of 981,841. The firm’s 50 day moving average is $122.54 and its 200-day moving average is $135.46. Repligen Corporation has a one year low of $100.99 and a one year high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The firm has a market cap of $8.29 billion, a PE ratio of 163.35, a P/E/G ratio of 2.67 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. During the same quarter last year, the business posted $0.39 EPS. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, analysts anticipate that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Repligen

A number of hedge funds and other institutional investors have recently bought and sold shares of RGEN. Bayforest Capital Ltd bought a new position in shares of Repligen during the fourth quarter valued at $32,000. Rachor Investment Advisory Services LLC acquired a new stake in Repligen during the fourth quarter worth approximately $33,000. Measured Wealth Private Client Group LLC acquired a new stake in Repligen during the third quarter worth approximately $29,000. Los Angeles Capital Management LLC bought a new stake in Repligen in the fourth quarter worth approximately $36,000. Finally, Farther Finance Advisors LLC increased its holdings in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 128 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on RGEN shares. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Wolfe Research initiated coverage on Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective on the stock. Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th. Weiss Ratings raised shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 7th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $164.64.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.